Yıl: 2023 Cilt: 54 Sayı: 1 Sayfa Aralığı: 54 - 58 Metin Dili: İngilizce DOI: 10.32552/2023.ActaMedica.877 İndeks Tarihi: 30-05-2023

Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study

Öz:
Purpose: Our aim in this study is to report the clinical features and treatment results of patients with conjunctival melanoma (CM) diagnosed in our clinic in the last 20 years. Materials and Methods: Demographic information, tumor diameter, accompanying melanosis, presence of recurrence and survival data were obtained retrospectively from the records of patients who had histopathologically confirmed CM diagnosis. Results: Conjunctival melanoma was detected in 84 eyes of 84 patients with a mean age of 61.5±24.6 years. In total 45.2% of the patients were female and 54.8% were male. The two most common primary lesion locations were limbus in 23.8% and bulbar conjunctiva in 22.6% of the patients. In ophthalmological evaluation, 46.3% of the patients had concomitant primary acquired melanosis. Appropriate surgical excision to the extent of the disease was performed primarily in all patients. After a median follow-up of 55 months, local recurrence rate was 45.2%, while the survival rate was found to be 74.3%. Conclusion: Conjunctival melanoma is a malignant neoplasm seen in advanced adulthood, often involving the bulbar surface of the conjunctiva. Even using the standard surgical approach, CM is associated with a 45.2% local recurrence rate and a 25.7% mortality rate. In our study, there was no clinical parameter that showed a statistically significant relationship with survival.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42(4):321-50.
  • [2] Larsen AC. Conjunctival malignant melanoma in Denmark. Epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Acta Ophthalmol. 2016;94(8):842.
  • [3] Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Populationbased assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43(11):3399-408.
  • [4] Shields CL, Alset AE, Boal NS, Casey MG, Knapp AN, Sugarman JA, et al. Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen Lecture. Am J Ophthalmol. 2017;173:106-33.
  • [5] Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA. Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila). 2017;6(2):109- 20.
  • [6] Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol. 1997;115(6):808-15.
  • [7] Bresler SC, Simon C, Shields CL, McHugh JB, Stagner AM, Patel RM. Conjunctival melanocytic lesions. Arch Pathol Lab Med. 2022;146(5):632-46.
  • [8] Jain P, Finger PT, Fili M, Damato B, Coupland SE, Heimann H, et al. Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. Br J Ophthalmol. 2021;105(10):1358-64.
  • [9] Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389-95 e1-2.
  • [10] Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497-507.
  • [11] Pacheco RR, Yaghy A, Dalvin LA, Vaidya S, Perez AL, Lally SE, et al. Conjunctival melanoma: outcomes based on tumour origin in 629 patients at a single ocular oncology centre. Eye (Lond). 2022;36(3):603-11.
  • [12] Vaidya S, Dalvin LA, Yaghy A, Pacheco R, Shields JA, Lally SE, et al. Conjunctival melanoma: Risk factors for recurrent or new tumor in 540 patients at a single ocular oncology center. Eur J Ophthalmol. 2021;31(5):2675-85.
  • [13] Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46(1):75-82.
  • [14] Jia S, Zhu T, Shi H, Zong C, Bao Y, Wen X, et al. American Joint Committee on Cancer Tumor Staging System predicts the outcome and metastasis pattern in conjunctival melanoma. Ophthalmology. 2022;129(7):771-80.
  • [15] Abt NB, Zhao J, Huang Y, Eghrari AO. Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades. Am J Otolaryngol. 2019;40(4):577-82.
APA Koç İ, Kapucu Y, KIRATLI H (2023). Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. , 54 - 58. 10.32552/2023.ActaMedica.877
Chicago Koç İrem,Kapucu Yasemin,KIRATLI HAYYAM Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. (2023): 54 - 58. 10.32552/2023.ActaMedica.877
MLA Koç İrem,Kapucu Yasemin,KIRATLI HAYYAM Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. , 2023, ss.54 - 58. 10.32552/2023.ActaMedica.877
AMA Koç İ,Kapucu Y,KIRATLI H Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. . 2023; 54 - 58. 10.32552/2023.ActaMedica.877
Vancouver Koç İ,Kapucu Y,KIRATLI H Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. . 2023; 54 - 58. 10.32552/2023.ActaMedica.877
IEEE Koç İ,Kapucu Y,KIRATLI H "Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study." , ss.54 - 58, 2023. 10.32552/2023.ActaMedica.877
ISNAD Koç, İrem vd. "Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study". (2023), 54-58. https://doi.org/10.32552/2023.ActaMedica.877
APA Koç İ, Kapucu Y, KIRATLI H (2023). Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. Acta Medica, 54(1), 54 - 58. 10.32552/2023.ActaMedica.877
Chicago Koç İrem,Kapucu Yasemin,KIRATLI HAYYAM Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. Acta Medica 54, no.1 (2023): 54 - 58. 10.32552/2023.ActaMedica.877
MLA Koç İrem,Kapucu Yasemin,KIRATLI HAYYAM Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. Acta Medica, vol.54, no.1, 2023, ss.54 - 58. 10.32552/2023.ActaMedica.877
AMA Koç İ,Kapucu Y,KIRATLI H Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. Acta Medica. 2023; 54(1): 54 - 58. 10.32552/2023.ActaMedica.877
Vancouver Koç İ,Kapucu Y,KIRATLI H Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study. Acta Medica. 2023; 54(1): 54 - 58. 10.32552/2023.ActaMedica.877
IEEE Koç İ,Kapucu Y,KIRATLI H "Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study." Acta Medica, 54, ss.54 - 58, 2023. 10.32552/2023.ActaMedica.877
ISNAD Koç, İrem vd. "Clinical Features and Treatment Results of Conjunctival Melanoma: Cross-Sectional Study". Acta Medica 54/1 (2023), 54-58. https://doi.org/10.32552/2023.ActaMedica.877